Nexalin's DIFS Tech Shows Statistically Significant Reductions in Self-Injury, Depression in Peer-Reviewed Pilot Study
NXL sits 19% above its 52-week low of $0.34 on light trading volume (0.2× avg).
Summary
Nexalin Technology announced the publication of a peer-reviewed pilot study in BMC Psychiatry, demonstrating its DIFS™ technology significantly reduced self-injury and depression symptoms in female adolescents. The study, involving six patients, also showed measurable changes in brain-network activity and connectivity, with no significant adverse effects. This positive clinical validation is a crucial development for Nexalin, especially given its recent financial baseline indicating a going concern warning and Nasdaq delisting threat. While preliminary and calling for larger randomized controlled trials, these findings provide important scientific support for the company's core technology and could be a catalyst for future development and potential funding, offering a glimmer of hope amidst its operational challenges. Investors will be watching for progress on larger trials and any subsequent regulatory or commercialization efforts.
At the time of this announcement, NXL was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.34 to $2.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.